Latest Breaking News On - Initial data expected - Page 1 : vimarsana.com

Indapta Therapeutics Receives U S FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin s Lymphoma and Myeloma

Indapta Therapeutics Receives U S FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin s Lymphoma and Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMark frohlichIndapta therapeutics incInitial data expectedSecond halfFast trackAccelerated approvalPriority reviewRolling reviewBiologic license applicationBlood advancesIndapta therapeutics

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical. | May 15, 2023

United statesNew zealandNew yorkUnited kingdomLos angelesAndrew bellingerSekar kathiresanJen robinsonAshlea kosikowskiResearch development rd expensesVerve therapeutics incDrug administrationAmerican college of cardiologyExchange commissionInitial data expectedSecond half

Verve Therapeutics Announces Pipeline Progress and

heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program,.

United statesNew zealandNew yorkUnited kingdomSekar kathiresanJen robinsonLos angelesAndrew bellingerAshlea kosikowskiResearch development rd expensesAmerican college of cardiologyExchange commissionDrug administrationVerve therapeutics incInitial data expectedSecond half